These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21737272)

  • 1. Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclopropyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydroimid azo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, part 1.
    Malancona S; Altamura S; Filocamo G; Kinzel O; Hernando JI; Rowley M; Scarpelli R; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4422-8. PubMed ID: 21737272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclo- propyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydro-imidazo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, part 2.
    Kinzel O; Alfieri A; Altamura S; Brunetti M; Bufali S; Colaceci F; Ferrigno F; Filocamo G; Fonsi M; Gallinari P; Malancona S; Hernando JI; Monteagudo E; Orsale MV; Palumbi MC; Pucci V; Rowley M; Sasso R; Scarpelli R; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4429-35. PubMed ID: 21737263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitors.
    Ontoria JM; Bufi LL; Torrisi C; Bresciani A; Giomini C; Rowley M; Serafini S; Bin H; Hao W; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5274-82. PubMed ID: 21803580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy.
    Tremblay MR; Nesler M; Weatherhead R; Castro AC
    Expert Opin Ther Pat; 2009 Aug; 19(8):1039-56. PubMed ID: 19505195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Hedgehog signaling and understanding refractory response to treatment with Hedgehog pathway inhibitors.
    Queiroz KC; Spek CA; Peppelenbosch MP
    Drug Resist Updat; 2012 Aug; 15(4):211-22. PubMed ID: 22910179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the design of Hedgehog pathway inhibitors for the treatment of malignancies.
    Banerjee U; Hadden MK
    Expert Opin Drug Discov; 2014 Jul; 9(7):751-71. PubMed ID: 24850423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy.
    Scales SJ; de Sauvage FJ
    Trends Pharmacol Sci; 2009 Jun; 30(6):303-12. PubMed ID: 19443052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and biological evaluation of phenyl imidazole analogs as hedgehog signaling pathway inhibitors.
    Sun C; Zhang Y; Wang H; Yin Z; Wu L; Huang Y; Zhang W; Wang Y; Hu Q
    Chem Biol Drug Des; 2021 Mar; 97(3):546-552. PubMed ID: 32946174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the hedgehog pathway: role in cancer and clinical implications of its inhibition.
    Cohen DJ
    Hematol Oncol Clin North Am; 2012 Jun; 26(3):565-88, viii. PubMed ID: 22520980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926).
    Tremblay MR; Lescarbeau A; Grogan MJ; Tan E; Lin G; Austad BC; Yu LC; Behnke ML; Nair SJ; Hagel M; White K; Conley J; Manna JD; Alvarez-Diez TM; Hoyt J; Woodward CN; Sydor JR; Pink M; MacDougall J; Campbell MJ; Cushing J; Ferguson J; Curtis MS; McGovern K; Read MA; Palombella VJ; Adams J; Castro AC
    J Med Chem; 2009 Jul; 52(14):4400-18. PubMed ID: 19522463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of hedgehog signaling pathway as a therapeutic strategy for pancreatic cancer.
    Xu FG; Ma QY; Wang Z
    Cancer Lett; 2009 Oct; 283(2):119-24. PubMed ID: 19232458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure activity relationship studies of imidazo[1,2-a]pyrazine derivatives against cancer cell lines.
    Myadaraboina S; Alla M; Saddanapu V; Bommena VR; Addlagatta A
    Eur J Med Chem; 2010 Nov; 45(11):5208-16. PubMed ID: 20832916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulators of the hedgehog signaling pathway.
    Heretsch P; Tzagkaroulaki L; Giannis A
    Bioorg Med Chem; 2010 Sep; 18(18):6613-24. PubMed ID: 20708941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of vitamin D3 A-ring analogues as Hedgehog pathway inhibitors.
    Banerjee U; Ghosh M; Kyle Hadden M
    Bioorg Med Chem Lett; 2012 Feb; 22(3):1330-4. PubMed ID: 22226657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hedgehog pathway inhibitors: a patent review (2009--present).
    Hadden MK
    Expert Opin Ther Pat; 2013 Mar; 23(3):345-61. PubMed ID: 23294277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agents targeting the Hedgehog pathway for pancreatic cancer treatment.
    Bisht S; Brossart P; Maitra A; Feldmann G
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1387-98. PubMed ID: 21154121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A molecular dynamics approach to identify an oxysterol-based hedgehog pathway inhibitor.
    Dash RC; Maschinot CR; Hadden MK
    Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):168-177. PubMed ID: 27825830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Hedgehog pathway in cancer.
    Rubin LL; de Sauvage FJ
    Nat Rev Drug Discov; 2006 Dec; 5(12):1026-33. PubMed ID: 17139287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy.
    Jin M; Kleinberg A; Cooke A; Gokhale PC; Foreman K; Dong H; Siu KW; Bittner MA; Mulvihill KM; Yao Y; Landfair D; O'Connor M; Mak G; Pachter JA; Wild R; Rosenfeld-Franklin M; Ji Q; Mulvihill MJ
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1176-80. PubMed ID: 21251824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationship studies and sleep-promoting activity of novel 1-chloro-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 2.
    Sifferlen T; Koberstein R; Cottreel E; Boller A; Weller T; Gatfield J; Brisbare-Roch C; Jenck F; Boss C
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3857-63. PubMed ID: 23719231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.